“Lysaker, 11 April 2014 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the treatment evaluation of the first dose cohort in the phase I/II study of Amphinex in combination with the cytotoxic agent gemcitabine in patients with inoperable bile duct cancer (cholangiocarcinoma) is completed. No safety concerns were observed at this dose level.”
http://inpublic.globenewswire.com/2014/04/11/PCI+Biotech+Successful+completion+of+the+first+dose+cohort+in+the+study+for+patients+with+inoperable+bile+duct+cancer+HUG1776700.html;jsessionid=1WTLTHxctWQ02LThTh9whgCTx8Pqyhy129rvc7sh4942MJp9sB1p!-1082031361
http://www.pcibiotech.com/content/bile-duct-cancer